Satellite Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.50 M
as on 31-07-2024
- Paid Up Capital ₹ 3.20 M
as on 31-07-2024
- Company Age 30 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.80 Cr
as on 31-07-2024
- Satisfied Charges ₹ 3.08 Cr
as on 31-07-2024
- Revenue -38.72%
(FY 2023)
- Profit -174.55%
(FY 2023)
- Ebitda -101.68%
(FY 2023)
- Net Worth -22.67%
(FY 2023)
- Total Assets 8.90%
(FY 2023)
About Satellite Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.50 M and a paid-up capital of Rs 3.20 M.
The company currently has active open charges totaling ₹4.80 Cr. The company has closed loans amounting to ₹3.08 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhharat Parekh, Vijay Kadam, and Dolly Parekh serve as directors at the Company.
- CIN/LLPIN
U24319MH1994PTC079317
- Company No.
079317
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Jun 1994
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Satellite Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bhharat Parekh  | Managing Director | 26-Sep-2018 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vijay Kadam | Director | 21-May-2021 | Current |
| Dolly Parekh | Director | 21-May-2021 | Current |
Financial Performance of Satellite Pharmaceuticals.
Satellite Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 38.72% decrease. The company also saw a substantial fall in profitability, with a 174.55% decrease in profit. The company's net worth observed a substantial decline by a decrease of 22.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Satellite Pharmaceuticals?
In 2023, Satellite Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 24 Jan 2020 | ₹1.00 Cr | Open |
Others Creation Date: 18 Dec 2018 | ₹3.10 Cr | Open |
Others Creation Date: 26 Mar 2018 | ₹5.00 M | Open |
How Many Employees Work at Satellite Pharmaceuticals?
Unlock and access historical data on people associated with Satellite Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Satellite Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Satellite Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
